High-dose chemotherapy with autologous stem cell rescue as a treatment modality for breast cancer

Breast Journal

Volumn 5, Issue 5, 1999, Pages 308-318

  Wingard, John R ^a   Moreb, Jan S ^a   Gaa, Rebecca I ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Adjuvant therapy; Breast cancer; High dose chemotherapy; Stem cell transplant

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; HEMOPOIETIC GROWTH FACTOR; MELPHALAN; METHOTREXATE; MITOXANTRONE; THIOTEPA; VINCRISTINE;

ARTICLE; BONE MARROW SUPPRESSION; BREAST CANCER; CLINICAL TRIAL; DRUG MEGADOSE; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MORTALITY; PHASE 2 CLINICAL TRIAL; QUALITY OF LIFE; REMISSION; STEM CELL TRANSPLANTATION;

EID: 0032845752     PISSN: 1075122X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1524-4741.1999.00004.x     Document Type: Article

References (50)

1. Zittoun RA, Mandelli F, Willemze R, et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. N Eng J Med 1995;332:217-23.
2. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Eng J Med 1996;335:91-97.
3. Phillip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Eng J Med 1995;333:1540-45.
4. Haioun C, Lepage E, Giselbrecht C, et al. Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: updated results of the prospective study LNH87-2. Groupe D'Etude des Lymphomes de l'Adulte. J Clin Oncol 1997;15: 1131-37.
5. Gianni AM, Bregni M, Siena S, et al. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Eng J Med 1997;336:1290-99.
6. Linch DC, Winfield D, Goldstone AH, et al. Dose intensification with autologous bone marrow transplantation in relapsed and resistant Hodgkin's disease: results of a GNLI randomized trial. Lancet 1993;341:1051-54.
7. Bonadonna G, Valagussa P. Dose-response effect of adjuvant chemotherapy in breast cancer. N Eng J Med 1981;304: 10-15.
8. Hryniuk W, Levine MN. Analysis of dose-intensity for adjuvant chemotherapy trials in stage II breast cancer. J Clin Oncol 1986;4:1162-70.
9. Hryniuk W, Bush H. The importance of dose-intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 1984;2:1281-88.
10. Redmond C, Fisher B, Wieand HS. The methodologic dilemma in retrospectively correlating the amount of chemotherapy received in adjuvant therapy protocols with disease-free survival. Cancer Treat Rep 1983;67:519-26.
11. Wood WC, Budman DR, Korzun AH, et al. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Eng J Med 1994;330:1253-59.
12. Bonneterie J, Roche H, Bremond A, et al. Results of a randomized trial of adjuvant chemotherapy with FEC50 vs FEC100 in high node-positive breast cancer patients. Proc Am Soc Clin Oncol 1998;17:124a.
13. Fisher B, Anderson S, Wickerham DL, et al. Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from the National Surgical Adjuvant Breast and Bowel Project B-22. J Clin Oncol 1997;15: 1858-69.
14. DeCillis A, Anderson S, Bryant J, et al. Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) on NSABP B-25: an update. Proc Am Soc Clin Oncol 1997;16:301a.
15. Henderson IC, Berry D, Demetri G, et al. Improved disease-free (DFS) and overall survival (OS) from the addition of sequential paclitaxel (T) but not from escalation of doxorubicin (A) dose level in the adjuvant chemotherapy of patients (pts) with node-positive breast cancer (BC). Proc Am Soc Clin Oncol 1998;17:101a.
16. Winer E, Berry D, Duggan D, et al. Failure of higher dose paclitaxel to improve outcome in patients with metastatic breast cancer - results from CALGB 9342. Proc Am Soc Clin Oncol 1998;17:101a.
17. Habeshaw T, Paul R, Jones R, et al. Epirubicin at two dose levels with prednisolone as treatment for advanced breast cancer: the results of a randomized trial. J Clin Oncol 1991;9: 295-304.
18. Bastholt L, Dalmark M, Gjedde SB, et al. Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: a randomized study of epirubicin at four different dose levels performed by the Danish Breast Cancer Cooperative Group. J Clin Oncol 1996;14: 1146-55.
19. 2) in the FEC regimen significantly increases response rate. An international randomized phase ni study in metastatic breast cancer. Ann Oncol 1997;8:155-62.
20. Focan C, Andrien JM, Closon MTH, et al. Dose-response relationship of epirubicin based first-line chemother-apy for advanced breast cancer: a prospective randomized trial. J Clin Oncol 1993;11:1253-63.
21. Marschner N, Kreienberg R, Souchon R, et al. Evaluation of the importance and relevance of dose intensity using epirubicin and cyclophosphamide in metastatic breast cancer: interim analysis of a prospective randomized trial. Semin Oncol 1994;21 (suppl 1):10-16.
22. Fountzilas G, Athanassiades A, Giannakkais T, et al. A randomized study of epirubicin monotherapy every four or every two weeks in advanced breast cancer. A Hellenic Cooperative Oncology Group study. Ann Oncol 1997;8:1213-20.
23. Mick R, Begg CB, Antman KH, et al. Diverse prognosis in metastatic breast cancer: Who should be offered alternative initial therapies? Breast Cancer Res Treat 1989;13:33-38.
24. Antman KH, Rowlings PA, Vaughan WP, et al. High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. J Clin Oncol 1997;15:1870-79.
25. Peters WP, Ross M, Vredenburgh J, et al. High-dose chemotherapy and autologous bone marrow support after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 1993;11:1132-43.
26. Gianni AM, Siena S, Bregni M, et al. Efficacy, toxicity and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes. Five-year results. J Clin Oncol 1997;15: 2312-21.
27. Lluch A, Azatra P, Solano C, et al. A case-control study of adjuvant high dose chemotherapy (HDCT) and peripheral blood stem cell (PBSC) transplantation or conventional chemotherapy (CT) in operable breast cancer (BC) patients (PTS) with 10 or more involved nodes. Proc Am Soc Clin Oncol 1998;17:155a, abstract 592.
28. Holland HK, Dix S, Geller RB, et al. Minimal toxicity and mortality in high risk breast cancer patients receiving high-dose cyclophosphamide, thiotepa and carboplatinum (Stamp V), autologous marrow/stem cell transplantation and comprehensive supportive care. J Clin Oncol 1996;14:1156-64.
29. Antman K, Ayash L, Elias A, et al. Phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy. J Clin Oncol 1992;10:102-10.
30. Peters WP, Shpall EJ, Jones RB, et al. High-dose combination alkylating agents with bone marrow as initial treatment for metastatic breast cancer.J Clin Oncol 1988;6:1368-75.
31. Greenberg PAC, Hortobagyi GN, Smith T, et al. Longterm follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 1997;14:2197-205.
32. Rahman ZU, Frye DK, Buzdar AU, et al. Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard dose doxorubicin containing chemotherapy in patients with metastatic breast cancer.J Clin Oncol 1997;15:3171-77.
33. Garcia-Carbonero R, Hidalgo M, Paz-Ares L, et al. Patient selection in high-dose chemotherapy trials: relevance in high-risk breast cancer. J Clin Oncol 1997;15:3178-84.
34. Canellos GP. Selection bias in trials of transplantation for metastatic breast cancer: Have we picked the apple before it was ripe? J Clin Oncol 1997;15:3169-70.
35. Berry DA, Broadwater G, Perry MC, et al. Conventional- vs high-dose therapy for metastatic breast cancer. Comparison of Cancer and Leukemia Group B (CALGB) Blood and Marrow Transplant Registry (ABMTR) patients. Proc Am Soc Clin Oncol 1999;18:128a, abstract 490.
36. Bezwoda WR, Seymour L, Dansey RD. High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial. J Clin Oncol 1995;13:2483-89.
37. Peters WP, Jones RB, Vredenburgh J, et al. A large, prospective, randomized trial of high-dose combination alkylating agents (CPB) with autologous cellular support (ABMS) as consolidation for patients with metastatic breast cancer achieving complete remission after intensive doxorubicin-based induction therapy (AFM). Proc Am Soc Clin Oncol 1996;15:121, abstract 149.
38. Stadtmauer EA, O'Neill A, Goldstein LJ, et al. Phase III randomized trial of high-dose chemotherapy (HDC) and stem cell support (SCT) shows no difference in overall survival or severe toxicity compared to maintenance chemotherapy with cyclophosphamide, methotrexate and 5-fluorouracil (CMF) for women with metastatic breast cancer who are responding to conventional induction chemotherapy: the "Philadelphia" Intergroup Study (PBT-1). Proc Am Soc Clin Oncol 1999;18:1a, abstract 1.
39. Lotz J-P, Cure H, Janvier M, et al. High-dose chemotherapy (HD-CT) with hematopoietic stem cell transplantation (HSCT) for metastatic beast cancer (MBC): results of the French Protocol PEGASE 04. Proc Am Soc Clin Oncol 1999; 18:43a, abstract 161.
40. Bezwoda WR, Dansey R, Seymour L. First line chemotherapy of advanced breast cancer with mitoxantrone, cyclophosphamide and vincristine. Oncology 1989;46:208-11.
41. Peters WP, Dansey R. New concepts in the treatment of breast cancer using high-dose chemotherapy. Cancer Chemother Pharmacol 1997;40(suppl):S88-S93.
42. Rodenhuis S, Richel DJ, van der Wall E, et al. Randomized trial of high-dose chemotherapy and hemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement. Lancet 1998;352:515-21.
43. Hortobagyi GN, Buzdar AU, Champlin R, et al. Lack of efficacy of adjuvant high-dose (HD) tandem combination chemotherapy (CT) for high-risk primary breast cancer (HRPBC) - a randomized trial. Proc Am Soc Clin Oncol 1998;17:123a, abstract 471.
44. Peters W, Rosner G, Vredenburgh J, et al. A prospective, randomized comparison of two doses of combination alkylating agents (AA) as consolidation after CAF in high risk primary breast cancer involving ten or more axillary lymph nodes (LN): Preliminary results of CALGB 9082/SWOG9114/NCIC MA-13. Proc Am Soc Clin Oncol 1999;18:1a, abstract 2.
45. The Scandinavian Breast Cancer Study Group 9401. Results from a randomized adjuvant breast cancer study with high dose chemotherapy with CTC supported by autologous bone marrow stem cells versus dose escalated and tailored FEC therapy. Proc Am Soc Clin Oncol 1999;18:2a, abstract 3.
46. Bezwoda WR. Randomized, controlled trial of high dose chemotherapy (HD-CNVp) versus standard dose (CAF) chemotherapy for high risk, surgically treated, primary breast cancer. Proc Am Soc Clin Oncol 1999;18:2a, abstract 4.
47. Schaake-Koning C, Hamersma-van der Linden E, Hart G, et al. Adjuvant chemo- and hormonal therapy in locally advanced breast cancer: a randomized clinical study. Int J Radiat Oncol Biol Phys 1985;11:1759-63.
48. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomized trials. Lancet 1998;352:930-2.
49. Winer EP, Herndon J, Peters WP, et al. Quality of life in patients with breast cancer randomized to high dose chemotherapy with bone marrow support vs. intermediate dose chemotherapy. CALGB 9066 (companion protocol to CALGB 9082). Proc Am Soc Clin Oncol 1999;18:412a, abstract 1593.
50. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Ewg J Med 1995;333:1540-45.